Clinical Trial Update: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating alpelisib plus fulvestrant for HR-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor and aromatase inhibi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING